Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.
Müller LME, Holmes M, Michael JL, Scott GB, West EJ, Scott KJ, Parrish C, Hall K, Stäble S, Jennings VA, Cullen M, McConnell S, Langton C, Tidswell EL, Shafren D, Samson A, Harrington KJ, Pandha H, Ralph C, Kelly RJ, Cook G, Melcher AA, Errington-Mais F. Müller LME, et al. Among authors: melcher aa. J Immunother Cancer. 2019 Jul 1;7(1):164. doi: 10.1186/s40425-019-0632-y. J Immunother Cancer. 2019. PMID: 31262361 Free PMC article. Clinical Trial.
Heated tumour cells of autologous and allogeneic origin elicit anti-tumour immunity.
Todryk SM, Eaton J, Birchall L, Greenhalgh R, Soars D, Dalgleish AG, Melcher AA, Pandha HS. Todryk SM, et al. Among authors: melcher aa. Cancer Immunol Immunother. 2004 Apr;53(4):323-30. doi: 10.1007/s00262-003-0452-1. Epub 2003 Nov 28. Cancer Immunol Immunother. 2004. PMID: 14648067 Free PMC article.
Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy.
Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M, Thompson B, Vile RG, Heinemann L, Pandha HS, Errington F, Melcher AA, Harrington KJ. Twigger K, et al. Among authors: melcher aa. Clin Cancer Res. 2008 Feb 1;14(3):912-23. doi: 10.1158/1078-0432.CCR-07-1400. Clin Cancer Res. 2008. PMID: 18245555
Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.
White CL, Twigger KR, Vidal L, De Bono JS, Coffey M, Heinemann L, Morgan R, Merrick A, Errington F, Vile RG, Melcher AA, Pandha HS, Harrington KJ. White CL, et al. Among authors: melcher aa. Gene Ther. 2008 Jun;15(12):911-20. doi: 10.1038/gt.2008.21. Epub 2008 Mar 6. Gene Ther. 2008. PMID: 18323793 Clinical Trial.
Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.
Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L, Ilett LJ, Prestwich R, Pandha HS, Coffey M, Selby P, Vile R, Harrington KJ, Melcher AA. Errington F, et al. Among authors: melcher aa. Gene Ther. 2008 Sep;15(18):1257-70. doi: 10.1038/gt.2008.58. Epub 2008 Apr 10. Gene Ther. 2008. PMID: 18401435 Free PMC article.
Immunotherapeutic potential of oncolytic virotherapy.
Prestwich RJ, Harrington KJ, Vile RG, Melcher AA. Prestwich RJ, et al. Among authors: melcher aa. Lancet Oncol. 2008 Jul;9(7):610-2. doi: 10.1016/S1470-2045(08)70163-3. Lancet Oncol. 2008. PMID: 18598928 No abstract available.
110 results